Variables | Caudate lobe metastases ( n = 45) | Number of caudate lobe metastases ( n = 41) | P value |
---|---|---|---|
Mean age (range) | 54.8 (29 to 85) | 53.5 (28 to 75) | 0.85 |
Gender M:F | 17:28 | 20:21 | 0.29 |
Comorbidities | 14 (31%) | 18 (43.9%) | 0.45 |
Carcinoid syndrome pre-TACE | 38 (84.4%) | 35 (85.4%) | .92 |
Primary resected | 17 (38%) | 27 (65.8%) | <0.03 |
Pancreas primary | 10 (22%) | 10 (24.4%) | 0.096 |
Tumor non-functional at presentation | 30 (65.9%) | 20 (48.9%) | 0.085 |
Tumor grade | 0.795 | ||
1 | 36 (80%) | 33 (80.5%) | |
2 | 4 (8.9%) | 4 (9.8%) | |
3 | 2 (4.4%) | 2 (4.9%) | |
Median pre-TACE pancreastatin level pg/ml (range) | 12,856 (84 to 56,200) | 5,985 (104 to 46,400) | <0.03 |
Median number of liver segments with metastases (range) | 8 (5 to 8) | 5 (2 to 8) | <0.05 |
Median (range) percentage of metastatic burden to liver | 71.4% (30 to 95) | 48.7% (5 to 95) | <0.01 |
Presence of extrahepatic disease | 32 (71%) | 22 (54%) | 0.24 |
Presence of lymph node metastases | 9 (22%) | 7 (15.6%) | 0.489 |